Tumor suppressor activities of the Fbw7 E3 ubiquitin ligase receptor.

Abstract:

:The F-box protein Fbw7/Sel-10/hCdc4/Ago, which is known to regulate ubiquitination and degradation of numerous important regulators of cell division and death including Notch, cyclin E, c-Jun and c-Myc, has been recently rediscovered as a p53-dependent tumor suppressor. Delineation of the mechanisms of Fbw7 anti-oncogenic activities and of its inactivation in human cancers is expected to gain an important insight into tumorigenesis.

journal_name

Cancer Biol Ther

journal_title

Cancer biology & therapy

authors

Fuchs SY

doi

10.4161/cbt.4.5.1703

keywords:

subject

Has Abstract

pub_date

2005-05-01 00:00:00

pages

506-8

issue

5

eissn

1538-4047

issn

1555-8576

pii

1703

journal_volume

4

pub_type

杂志文章,评审
  • Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo.

    abstract::Cancer cells convert glucose preferentially to lactate even in the presence of oxygen (aerobic glycolysis-Warburg effect). New concepts in cancer treatment aim at inhibition of aerobic glycolysis. Pyruvate dehydrogenase converts pyruvate to acetylCoA thus preventing lactate formation. Therefore, the aim of this study ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.22003

    authors: Feuerecker B,Pirsig S,Seidl C,Aichler M,Feuchtinger A,Bruchelt G,Senekowitsch-Schmidtke R

    更新日期:2012-12-01 00:00:00

  • Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts.

    abstract::The Bin1/Amphiphysin2 gene encodes several alternately spliced BAR adapter proteins that have been implicated in membrane-associated and nuclear processes. Bin1 expression is often attenuated during tumor progression and Bin1 splice isoforms that localize to the nucleus display tumor suppressor properties. While these...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.12.1232

    authors: Muller AJ,DuHadaway JB,Donover PS,Sutanto-Ward E,Prendergast GC

    更新日期:2004-12-01 00:00:00

  • Ototoxicity in patients with invasive ductal breast cancer who were treated with docetaxel: report of two cases.

    abstract::Docetaxel is an important anti-microtubule agent used to treat a variety of solid tumors, including breast cancer; notably, docetaxel-containing regimens improve outcomes for patients in metastatic, adjuvant, and neoadjuvant settings. However, the effectiveness of docetaxel in clinical practice can be compromised by s...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1831370

    authors: Xuan L,Sun B,Meng X,Liu C,Cong Y,Wu S

    更新日期:2020-11-01 00:00:00

  • Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway.

    abstract::Chronic myeloid leukemia (CML) progresses from a chronic phase to a deadly blast crisis phase. While it is known that BCR-ABL initiates the disease and that secondary molecular and genetic abnormalities likely contribute to progression of the disease to blast crisis, details regarding the mechanism(s) of blast phase p...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.10.10.14010

    authors: Griner LN,Reuther GW

    更新日期:2010-11-15 00:00:00

  • Upregulation of microRNA-129-5p inhibits cell invasion, migration and tumor angiogenesis by inhibiting ZIC2 via downregulation of the Hedgehog signaling pathway in cervical cancer.

    abstract::Recently, some studies have placed additional research focus on microRNAs (miRNAs) in a bid to discover novel therapeutic approaches for cervical cancer (CC), which is one of the most common female reproductive tract malignancies with high rates of morbidity and mortality. Hence, the aim of the present study was to ev...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2018.1491497

    authors: Wang YF,Yang HY,Shi XQ,Wang Y

    更新日期:2018-01-01 00:00:00

  • Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.

    abstract::The synergistic effect of combined drug therapy provides an enhanced treatment for advanced liver cancer. We aimed to investigate the underlying mechanism of cetuximab sensitization by rapamycin in hepatoma cells. Four hepatoma cell lines, HepG2, HuH7, SNU-387, and SNU-449, were treated with cetuximab or cetuximab plu...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29113

    authors: Chen W,Hu QD,Xia XF,Liang C,Liu H,Zhang Q,Ma T,Liang F,Liang TB

    更新日期:2014-08-01 00:00:00

  • Chetomin, a Hsp90/HIF1α pathway inhibitor, effectively targets lung cancer stem cells and non-stem cells.

    abstract::Non-small cell lung cancer (NSCLC) remains recalcitrant to effective treatment due to tumor relapse and acquired resistance. Cancer stem cells (CSCs) are believed to be one mechanism for relapse and resistance and are consequently considered promising drug targets. We report that chetomin, an active component of Chaet...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1763147

    authors: Min S,Wang X,Du Q,Gong H,Yang Y,Wang T,Wu N,Liu X,Li W,Zhao C,Shen Y,Chen Y,Wang X

    更新日期:2020-08-02 00:00:00

  • The genetics of FANCC and FANCG in familial pancreatic cancer.

    abstract::Patients with Fanconi anemia (FA) display a wide variety of defects including bone marrow failure and a high risk of developing cancer. Multiple Fanconi genes exist whose proteins form a complex that along with BRCA1 is important for the translocalization of FANCD2 to nuclear foci. With BRCA2 and RAD51, this complex i...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.2.609

    authors: Rogers CD,van der Heijden MS,Brune K,Yeo CJ,Hruban RH,Kern SE,Goggins M

    更新日期:2004-02-01 00:00:00

  • DNA methylation regulates MicroRNA expression.

    abstract::MicroRNAs (miRNAs), an important class of small regulatory molecules for gene expression, are transcribed by RNA polymerase II. But little is known about the mechanisms that control miRNA expression. Comparing miRNA expression profiles between colon cancer cell line HCT 116 and its derivative, DNA methyltransferase 1 ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.8.4486

    authors: Han L,Witmer PD,Casey E,Valle D,Sukumar S

    更新日期:2007-08-01 00:00:00

  • Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses.

    abstract::As a kinase at the crossroads of numerous metabolic and cell growth signaling pathways, glycogen synthase kinase-3 beta (GSK-3β) is a highly desirable therapeutic target in cancer. Despite its involvement in pathways associated with the pathogenesis of several malignancies, no selective GSK-3β inhibitor has been appro...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.1080/15384047.2019.1595283

    authors: Sahin I,Eturi A,De Souza A,Pamarthy S,Tavora F,Giles FJ,Carneiro BA

    更新日期:2019-01-01 00:00:00

  • Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study.

    abstract::The surprising results published by FIRE-3 revealed that the overall survival (OS) of RAS wild-type metastatic colorectal cancer (mCRC) patients treated with Cetuximab(Cmab) and FOLFIRI combination was prolonged to 33.1 months. The substantial increase in testing and treatment costs, however, impose a considerable hea...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1095398

    authors: Wen F,Yang Y,Zhang P,Zhang J,Zhou J,Tang R,Chen H,Zheng H,Fu P,Li Q

    更新日期:2015-01-01 00:00:00

  • Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer.

    abstract::Breast cancer is one of the most commonly diagnosed malignancies in women. Despite the remarkable success of mammography screening and use of adjuvant systemic therapy, it is estimated that approximately 200,000 new diagnoses will be made this year and 40,000 deaths will occur due to this disease (American Cancer Soci...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.9.17677

    authors: Rosca EV,Koskimaki JE,Pandey NB,Wolff AC,Popel AS

    更新日期:2011-11-01 00:00:00

  • The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein.

    abstract::CP-31398, a styrylquinazoline, emerged from a screen for therapeutic agents that restore a wild-type DNA-binding conformation of mutant p53 to suppress tumors in-vivo (Science 286, 2507, 1999). We investigated the growth inhibitory mechanism of CP-31398 using nine human cancer cell lines containing wild-type, mutant o...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.1.1.41

    authors: Takimoto R,Wang W,Dicker DT,Rastinejad F,Lyssikatos J,el-Deiry WS

    更新日期:2002-01-01 00:00:00

  • C1B domain peptide of protein kinase Cγ significantly suppresses growth of human colon cancer cells in vitro and in an in vivo mouse xenograft model through induction of cell cycle arrest and apoptosis.

    abstract::Two peptides derived from the C1B domain of protein kinase Cγ (PKCγ) were shown to associate with classical PKC isozymes and modulate their activities. These C1B peptides are designated C1B1 (amino acid residues 101-112) and C1B5 (residues 141-151). Since PKC enzyme activity is shown to be involved in colon cancer dev...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.20840

    authors: Kawabata A,Matsuzuka T,Doi C,Seiler G,Reischman J,Pickel L,Ayuzawa R,Nguyen TA,Tamura M

    更新日期:2012-08-01 00:00:00

  • Microarray data simulator for improved selection of differentially expressed genes.

    abstract::The development of microarray technology has allowed researchers to measure expression levels of thousands of genes simultaneously. Analysis of these data requires the best normalization and statistical approaches to account for the biological and technical variability inherent in the technique. To approach this probl...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.2.4.431

    authors: Singhal S,Kyvernitis CG,Johnson SW,Kaiser LR,Liebman MN,Albelda SM

    更新日期:2003-07-01 00:00:00

  • Multiplying therapies and reducing toxicity in metastatic melanoma.

    abstract::Prior to 2011, only 2 systemic treatments were approved for the treatment of melanoma and these had limited efficacy. In the past 4 years, 6 novel agents have received FDA approval. Herein, we will focus on 4 recently published NEJM papers reporting the results of clinical trials, comprising 4 agents targeting the MAP...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1046650

    authors: Massey PR,Prasad V,Figg WD,Fojo T

    更新日期:2015-01-01 00:00:00

  • A homologous promoterless K-ras cDNA targeting endogenous K-ras expression inhibits human pancreatic cancer cell growth in vitro and in vivo.

    abstract::It has been reported that the local introduction of a promoter-less DNA containing the complementary DNA (cDNA) sequence of a gene could induce gene-specific silencing in plants. The feasibility of this kind of silencing in human cancer cells is as yet unknown. The current study was designed to investigate the anti-tu...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.7.10.6586

    authors: Ren XY,Liang ZY,Shi XH,Liu TH

    更新日期:2008-10-01 00:00:00

  • Inactivation of miR-100 combined with arsenic treatment enhances the malignant transformation of BEAS-2B cells via stimulating epithelial -mesenchymal transition.

    abstract::Chronic arsenic treatment induces epithelial-mesenchymal transition (EMT) and promotes tumorigenicity, but the mechanism is unclear. MiR-100 has been shown to be involved in this biologic process. In this study, we hypothesize that inactivation of miR-100 combined with low concentration of arsenic exposure could promo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2017.1345393

    authors: Yang J,Chen Z,Wang X,Xu M,Fang H,Li F,Liu Y,Jiang Y,Ding Y,Li J,Wang S

    更新日期:2017-12-02 00:00:00

  • The biology of hormone refractory breast and prostate cancer: An NCI workshop report.

    abstract::The molecular regulation of growth and progression of hormone refractory breast and prostate cancers remains challenging. The Division of Cancer Biology, NCI organized a small "think tank" style workshop and invited scientists in relevant areas to assess the state of science on the biology of hormone refractory tumors...

    journal_title:Cancer biology & therapy

    pub_type:

    doi:10.4161/cbt.8.21.9918

    authors: Mohla S,Stearns V,Sathyamoorthy N,Rosenfeld MG,Nelson P

    更新日期:2009-11-01 00:00:00

  • Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line.

    abstract::Silibinin, derived from milk thistle extract, has been shown to inhibit growth factor receptor-mediated mitogenic and cell survival signaling, and to alter cell cycle regulators. Alteration in pathways regulating cell growth likely account for silibinin's inhibition of tumor growth. Since the epidermal growth factor r...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.2.5.452

    authors: Qi L,Singh RP,Lu Y,Agarwal R,Harrison GS,Franzusoff A,Glode LM

    更新日期:2003-09-01 00:00:00

  • DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a.

    abstract::MDM2 antagonists stabilize and activate wild-type p53, and histone methyltransferase (HMT) inhibitors reduce methylation on histone lysines and arginines. Both MDM2 antagonists and HMT inhibitors are being developed as cancer therapeutics. Wild-type p53 expressing HCT116 colon cancer cells were resistant to apoptosis ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2018.1433500

    authors: Zhou Y,Perez RE,Duan L,Maki CG

    更新日期:2018-06-03 00:00:00

  • Oncogenic Ras modulates p38 MAPK-mediated inflammatory cytokine production in glioblastoma cells.

    abstract::Inflammation is an important factor promoting the progression of glioblastoma. In the present study we examined the contribution of Ras signaling and TNFα/IL-1β cytokines to the development of the glioblastoma inflammatory microenvironment. Enhanced activation of Ras through de-regulated activation of receptor tyrosin...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2016.1139249

    authors: Munoz L,Yeung YT,Grewal T

    更新日期:2016-04-02 00:00:00

  • The promising role of nivolumab in renal cell cancers.

    abstract::The therapeutic efficacy of checkpoint inhibitors across numerous tumor types has resulted in approval for neoplasms such as melanoma and lung cancer. Nivolumab is a fully humanized IgG4 antibody that inhibits immune checkpoint between programmed death 1 (PD-1) on T cells and PD-1 ligand 1 (PD-L1) and ligand 2 (PD-L2)...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2016.1139269

    authors: Gupta K,Tiu DY,Tiu J,Aragon-Ching JB

    更新日期:2016-01-01 00:00:00

  • Inhibition of Hsp27 and Hsp40 potentiates 5-fluorouracil and carboplatin mediated cell killing in hepatoma cells.

    abstract::Heat shock proteins (Hsps) modulate several cellular functions and are ubiquitously present in cell. Here, we investigated alterations in the expression of Hsps and explored functional consequences of the same. Moreover, effect of quercetin (Qctn), an inhibitor of Hsps, on chemotherapeutic drugs treatment in hepatoma ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.8.22.9687

    authors: Sharma A,Upadhyay AK,Bhat MK

    更新日期:2009-11-01 00:00:00

  • Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers.

    abstract::Current risk stratification using clinical and pathological parameters in patients with urothelial carcinoma of the bladder (UCB) is insufficient. Additional information on the tumor biology can be derived from molecular biomarkers assessed in surgical UCB specimens and the predictive accuracy of oncologic end points ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.10.5.13022

    authors: Bolenz C,Lotan Y

    更新日期:2010-09-01 00:00:00

  • Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1.

    abstract::The intrinsic or acquired resistance to multiple drugs (MDR) of cancer cells remains one of the main obstacles for chemotherapy. Development of small molecule targeting to hypoxia inducible factor-1 (HIF-1) has been recently proposed as strategy for treatments of drug-resistant solid tumors. In the present study, emod...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.7.3.5457

    authors: Huang XZ,Wang J,Huang C,Chen YY,Shi GY,Hu QS,Yi J

    更新日期:2008-03-01 00:00:00

  • Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12.

    abstract::bcr/abl fusion gene is thought to be a promising target for chronic myelogenous leukemia (CML) patients to enhance immune response after attaining complete remission. In this study, we sought to enhance cellular immunity by co-expression of BCR/ABL and murine IL-12 gene on the tumor cell surface as a glycosyl-phosphat...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.10.17674

    authors: Tao K,Li YJ,Wang D,Qi JY,Deng YP,Wang HX,Hu J,Feng WL

    更新日期:2011-11-15 00:00:00

  • Divergent control of Cav-1 expression in non-cancerous Li-Fraumeni syndrome and human cancer cell lines.

    abstract::Li-Fraumeni syndrome (LFS) is primarily characterized by development of tumors exhibiting germ-line mutations in the p53 gene. Cell lines developed from patients of a LFS family have decreased p53 activity as evidenced by the absence of apoptosis upon etoposide treatment. To test our hypothesis that changes in gene ex...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.22621

    authors: Sherif ZA,Sultan AS

    更新日期:2013-01-01 00:00:00

  • MicroRNA-23a depletion promotes apoptosis of ovarian cancer stem cell and inhibits cell migration by targeting DLG2.

    abstract::Ovarian cancer (OC) is xenogeneic that is influenced by many generated factors related to epigenetic factors to accelerate tumor metastasis. This study was conducted with the objective of investigating the effect of microRNA-23a-3p (miR-23a) on the biological characteristics of OC stem cells by targeting discs large h...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2019.1579960

    authors: Zhuang RJ,Bai XX,Liu W

    更新日期:2019-01-01 00:00:00

  • Gene expression alterations in formalin-fixed, paraffin-embedded Barrett esophagus and esophageal adenocarcinoma tissues.

    abstract:BACKGROUND AND AIM:Widespread applicability of tissue-based mRNA expression screening for Barrett esophagus (BE) is likely to require (1) accurate methods for assaying archival formalin-fixed, paraffin-embedded (FFPE) histopathology specimens taken at endoscopy, and (2) validation studies of promising biomarkers in dif...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.10.2.12166

    authors: Botelho NK,Schneiders FI,Lord SJ,Freeman AK,Tyagi S,Nancarrow DJ,Hayward NK,Whiteman DC,Lord RV

    更新日期:2010-07-15 00:00:00